Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
Key facts
- Who runs it
- Neurocrine Biosciences
- Where
- Ann Arbor, Atlanta, Aurora, Bethesda, Boston, Dallas, Great Neck, Indianapolis, Los Angeles, Minneapolis, New York, Philadelphia, Pittsburgh, Rochester, San Diego, San Francisco, Seattle, St Louis, Tulsa, and Winston-Salem, United StatesSee the 20 sitesAlso in 17 other countries, 42 sites
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 182 people enrolled
- Started
- 16 Dec 2020
- Expected to end
- Aug 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Crinecerfont
- Placebo
- Record updated
- 11 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Be willing and able to adhere to the study procedures, including all requirements at the study center and return for the follow-up visit
- Have a medically confirmed diagnosis of classic CAH due to 21-hydroxylase deficiency
- Be on a stable steroid regimen
- Participants of childbearing potential must agree to use an acceptable method of contraception during the study
Who cannot take part
- Have received any other investigational drug within 30 days before initial screening or plan to use an investigational drug (other than the study drug) during the study
- Have current substance dependence, or current substance (drug) or alcohol abuse
- Have had a blood loss ≥550 mL or donated blood or blood products within 8 weeks prior to the study
- Have a history of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic glucocorticoid therapy
- Have a clinically significant unstable medical condition or chronic disease other than CAH
- Have a history of cancer unless considered cured
- Have a known history of clinically significant arrhythmia or abnormalities on ECG
- Have a known hypersensitivity to any corticotropin releasing hormone receptor antagonists
- Have a diagnosis of any of the other known forms of classic CAH
- Are pregnant
Where in United States
Also in 17 other countries, 42 sites
- Ann Arbor, MichiganHospital not named in the registry
- Atlanta, GeorgiaHospital not named in the registry
- Aurora, ColoradoHospital not named in the registry
- Bethesda, MarylandHospital not named in the registry
- Boston, MassachusettsHospital not named in the registry
- Dallas, TexasHospital not named in the registry
- Great Neck, New YorkHospital not named in the registry
- Indianapolis, IndianaHospital not named in the registry
- Los Angeles, CaliforniaHospital not named in the registry
- Minneapolis, MinnesotaHospital not named in the registry
- New YorkHospital not named in the registry
- Philadelphia, PennsylvaniaHospital not named in the registry
- Pittsburgh, PennsylvaniaHospital not named in the registry
- Rochester, New YorkHospital not named in the registry
- San Diego, CaliforniaHospital not named in the registry
- San Francisco, CaliforniaHospital not named in the registry
- Seattle, WashingtonHospital not named in the registry
- St Louis, MissouriHospital not named in the registry
- Tulsa, OklahomaHospital not named in the registry
- Winston-Salem, North CarolinaHospital not named in the registry
About the trial
What the trial wants to find out
This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult participants with classic CAH due to 21-hydroxylase deficiency. The study consists of a 24-week randomized, double-blind, placebo-controlled period, followed by 1 year of active treatment with crinecerfont. Subsequently, participants may elect to participate in the open-label extension (OLE) period. The duration of participation in the study is approximately 20 months for the core study and will be a variable amount of time per participant for the OLE (estimated to be approximately 3 years).
The 2 groups in the trial
- PlaceboPlacebo, for comparison
Placebo capsule, administered orally, twice daily for 24 weeks, followed by active treatment with crinecerfont for at least 1 year.
Treatment: Crinecerfont and Placebo
- CrinecerfontTreatment being tested
Crinecerfont capsule, administered orally, twice daily for 24 weeks during the placebo-controlled treatment period, followed by active treatment with crinecerfont for at least 1 year.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
- Publications
- Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.The New England journal of medicine, 2024
- Record updated
- 11 May 2026